Evolus (EOLS)
Nasdaq Market Closed
Evolus, Inc. is a medical aesthetics company focused on the self-pay segment of the beauty market, where patients typically pay directly for elective treatments rather than relying on insurance reimbursement. The company positions itself as a “performance beauty” business, combining pharmaceutical-grade injectable products with a consumer-oriented commercial model aimed at aesthetic practices and their patients.
Its lead product is Jeuveau, a purified botulinum toxin type A formulation used to temporarily improve the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults. Jeuveau competes in the neuromodulator market, where physicians and aesthetic practitioners use injectable toxins to relax targeted facial muscles and reduce the appearance of wrinkles. Outside the United States, the same product is marketed in certain regions under local branding, including Nuceiva.
Evolus is also expanding into injectable dermal fillers through Evolysse, a family of hyaluronic acid gels designed for common facial aesthetic applications such as mid-face volume, nasolabial folds, lips, and the eye area. Hyaluronic acid fillers are used to restore volume, shape facial contours, and smooth lines, making them a complementary category to neurotoxins in aesthetic clinics.
The company operates commercially across the United States, Canada, Europe, and Australia. Its strategy centers on building a focused aesthetics portfolio, supporting providers with brand marketing and practice-oriented tools, and competing in large, recurring treatment categories within non-surgical facial aesthetics.
Last updated
- Market Cap
- 397.1M
- P/E
- —
- P/FCF
- —
- P/S
- 1.32
- Enterprise Value
- 534M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
4 Stocks to Buy for Attractive Earnings Acceleration
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
Why sales of Botox and other cosmetic injections may be resilient in a recession
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 397.1M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 534M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -13.8
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.32
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -36.56
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.77
- EPS
- -0.66
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -43.59M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 150.87%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -19.68%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- -6.49
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.04
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.68
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.73
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 886.96K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 6.03
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 73.14M | 90.3M | 68.97M | 69.39M | 68.52M |
| Gross profit | 48.9M | 59.29M | 45.84M | 45.32M | 46.66M |
| Operating income | -6.85M | 4.22M | -11.5M | -10.21M | -15.17M |
| EBITDA | -4.5M | 6.47M | -8.11M | -8.47M | -13.61M |
| Net income | -10.67M | 130K | -15.74M | -17.14M | -18.89M |
| Basic EPS | -0.16 | 0 | -0.24 | -0.27 | -0.3 |
| Diluted EPS | -0.16 | 0 | -0.24 | -0.27 | -0.3 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 220.65M | 225.87M | 219M | 228.8M | 213.36M |
| Total liabilities | 249.43M | 248.97M | 247.76M | 247.46M | 219.97M |
| Total equity | -28.78M | -23.11M | -28.76M | -18.65M | -6.6M |
| Cash & equivalents | 49.79M | 53.83M | 43.52M | 61.74M | 67.89M |
| Current assets | 138.92M | 142.92M | 134.89M | 144.97M | 131.72M |
| Current liabilities | 68.02M | 75.31M | 66.71M | 63.75M | 56.23M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -9.95M | 12.83M | -14.67M | -24.79M | -15.63M |
| Investing cash flow | -1.69M | -2.17M | -2.16M | -2.27M | -1.86M |
| Financing cash flow | 7.62M | 77K | -1.77M | 20.66M | -1.63M |
| Change in cash | -4.03M | 10.3M | -18.22M | -6.16M | -19.06M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| edgar index | 10-Q — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | ARS — Evolus, Inc. | View Filing | |
| edgar index | DEF 14A — Evolus, Inc. | View Filing | |
| edgar index | DEFA14A — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — Evolus, Inc. | View Filing | |
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| edgar index | 10-K — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| form 4 | Form 4 — GILL DAVID N | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — Malik Vikram | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| form 4 | Form 4 — White Albert G III | View Filing | |
| form 4 | Form 4 — Mitchell Tatjana | View Filing | |
| form 4 | Form 4 — Mitchell Tatjana | View Filing | |
| form 4 | Form 4 — Mitchell Tatjana | View Filing | |
| form 4 | Form 4 — Stewart Brady | View Filing | |
| form 4 | Form 4 — Parschauer Karah Herdman | View Filing | |
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| form 4 | Form 4 — Avelar Rui | View Filing | |
| form 4 | Form 4 — MOATAZEDI DAVID | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Evolus, Inc. | View Filing | |
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| edgar index | 10-Q — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| edgar index | 8-K — Evolus, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Mitchell Tatjana | View Filing | |
| form 4 | Form 4 — Mitchell Tatjana | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing | |
| form 4 | Form 4 — Yamagishi-Dressler Tomoko | View Filing | |
| edgar index | SCHEDULE 13G — Evolus, Inc. | View Filing | |
| edgar index | 4 — Evolus, Inc. | View Filing |